Spike Protein News and Research

RSS

Predicting immunity evasion of SARS-CoV-2 Omicron variant of concern

In a new study, a team of researchers assessed the affinity of the SARS-CoV-2 Omicron variant of concern towards major histocompatibility complex (MHC) binding

4 Feb 2022

Global efforts to track COVID-19 variants grossly underreported a probable variant of concern in Nigeria

If the United States ignores COVID-19 in Nigeria, we forgo global genomic surveillance at our own peril, reports a new Northwestern Medicine study published in Nature Communications.

3 Feb 2022

Studying the efficacy of a SARS-CoV-2 vaccine booster dose

In a new study, a team of researchers assessed the efficacy of booster doses of Ad26.COV2.S (Jansen) SARS-CoV-2 vaccine.

3 Feb 2022

Exploring human milk oligosaccharides as a method of COVID-19 prevention

New research was conducted to ascertain whether antiviral and immunomodulatory activities of human milk oligosaccharides can be efficacious in the prevention and treatment against COVID-19.

3 Feb 2022

Neutralizing antibodies against SARS-CoV-2 variants induced by homologous and heterologous COVID-19 booster vaccination

In this study, scientists focused on identifying tentative cut-offs for large-scale evaluations of immune protection against SARS-CoV-2 and its variants.

3 Feb 2022

SARS-CoV-2 omicron variant shown to replicate less efficiently in human lungs

A new study revealed that the omicron variant replicates more effectively in the human bronchus than other SARS-CoV-2 variants, yet this new variant has lower replication competence in the lungs.

2 Feb 2022

The ability of individuals to cross-recognize the Omicron spike protein following vaccination or prior infection

Scientists studied the ability of T cells to react with the Omicron spike.

2 Feb 2022

New nanoparticle SARS-CoV-2 vaccine shows stronger, broader, and more durable protection

The first generation of COVID-19 vaccines have been highly effective, but also have limitations: their efficacy can wane without a booster shot, and they may be less effective against some variants.

2 Feb 2022

Research supports the need for a 3rd mRNA COVID vaccine in patients taking immunosuppressants

New research posted to the medRxiv* preprint server finds patients with immune-mediated inflammatory diseases undergoing anti-TNF therapy had the greatest reduction of antibody levels three months after vaccination. In addition, they had weaker neutralization responses towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

1 Feb 2022

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

A team of scientists from the United States has recently demonstrated that current coronavirus disease 2019 (COVID-19) vaccines induce robust spike-specific T cell responses against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Feb 2022

Developing post-vaccination SARS-CoV-2 standard reference sera

A new study reports the generation of reference sera reagents that were obtained from subjects vaccinated with one of four COVID-19 vaccines.

1 Feb 2022

Study shows mRNA booster dose eliminates immune escape observed with SARS-CoV-2 Omicron

Researchers examined total and neutralizing antibodies to the spike protein of SARS-CoV-2, and neutralizing antibodies against Washington-1 (WA-1) and variants of concern (VOC) including Beta, Delta, and Omicron in a longitudinal cohort.

31 Jan 2022

Study assesses anti-SARS-CoV-2 antibody response to mRNA-1273 vaccination over time

A new study has assessed the antibody responses to the mRNA-1273 Moderna vaccine over time.

31 Jan 2022

Study highlights importance of immunizing and boosting PAD syndromes patients with SARS-CoV-2 mRNA vaccines

A new study posted to the medRxiv* preprint server has evaluated the effect of mRNA-based COVID-19 vaccination and boosting strategy on serum antibody responses in PAD patients against the original SARS-CoV-2 strain and circulating variants.

31 Jan 2022

Preliminary study assesses durability of NAb titers against Omicron after mRNA-1273 booster

Researchers from Moderna, the developers of one key vaccine, have been investigating its ability to protect against the Omicron variant.

31 Jan 2022

Research shows rapid antigen tests can detect SARS-CoV-2 variants, including Omicron

Researchers determined the analytical sensitivity of a CE-marked fast antigen with the SARS-CoV-2 Omicron, Delta, Alpha, and Gamma variants.

31 Jan 2022

Yellow fever vaccine-vectored YF-S0 as a potent COVID-19 vaccine candidate

In a new study, a team of researchers developed YF-S0, an exceptionally potent COVID-19 vaccine candidate using live-attenuated yellow fever vaccine YF17D as a vector.

31 Jan 2022

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

In a new study, a team of researchers discovered S-217622, a non-covalent SARS-CoV-2 3C-like protease (3CLpro) inhibitor clinical candidate for the treatment of COVID-19.

31 Jan 2022

Three exposures to SARS-CoV-2 spike protein can induce robust neutralizing antibodies against variants

In a new study, scientists revealed that three consecutive exposures SARS-CoV-2 spike protein through infection, vaccination, or both can induce strong neutralizing antibodies against a wide variety of viral variants, including omicron.

31 Jan 2022

Researchers create model to predict COVID-19 mortality

In a new study, researchers have created a model that can help determine the outcome of COVID-19 infection in patients in the ICU.

31 Jan 2022

Spike Protein News and Research

Predicting immunity evasion of SARS-CoV-2 Omicron variant of concern

Global efforts to track COVID-19 variants grossly underreported a probable variant of concern in Nigeria

Studying the efficacy of a SARS-CoV-2 vaccine booster dose

Exploring human milk oligosaccharides as a method of COVID-19 prevention

Neutralizing antibodies against SARS-CoV-2 variants induced by homologous and heterologous COVID-19 booster vaccination

SARS-CoV-2 omicron variant shown to replicate less efficiently in human lungs

The ability of individuals to cross-recognize the Omicron spike protein following vaccination or prior infection

New nanoparticle SARS-CoV-2 vaccine shows stronger, broader, and more durable protection

Research supports the need for a 3rd mRNA COVID vaccine in patients taking immunosuppressants

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

Developing post-vaccination SARS-CoV-2 standard reference sera

Study shows mRNA booster dose eliminates immune escape observed with SARS-CoV-2 Omicron

Study assesses anti-SARS-CoV-2 antibody response to mRNA-1273 vaccination over time

Study highlights importance of immunizing and boosting PAD syndromes patients with SARS-CoV-2 mRNA vaccines

Preliminary study assesses durability of NAb titers against Omicron after mRNA-1273 booster

Research shows rapid antigen tests can detect SARS-CoV-2 variants, including Omicron

Yellow fever vaccine-vectored YF-S0 as a potent COVID-19 vaccine candidate

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

Three exposures to SARS-CoV-2 spike protein can induce robust neutralizing antibodies against variants

Researchers create model to predict COVID-19 mortality

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News